TheDoseReport published a consumer-oriented guide comparing the GLP-1 medications semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) for weight management. The piece explains how GLP-1 receptor agonists work, citing average weight loss of about 13.7% for semaglutide and 20.2% for tirzepatide in clinical trials. It also discusses dosing, cost differences, and the idea that the best choice depends on individual health factors.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.